Biotech Catalysts This Week: 1 FDA Decision, 1 Trial Completion and 8 New Financings (Oct 11-18, 2026)
This week centers on IRD’s PDUFA date of 2026-10-17 for Phentolamine Ophthalmic Solution 0.75%, alongside an estimated primary completion date for BMY’s LIBREXIA-STROKE trial. Last week brought three new company-guided timelines from EPRX, OSTX and BNTC, three trial status changes including two for ARWR, and twelve key SEC filings, with no delays or discontinuations recorded.
At a glance: this week 1 FDA decision date, 1 Phase 2 or 3 trial reaching primary completion and 8 new financing filings. Last week: 3 new timelines announced and 12 key SEC filings.
🔄 What Changed Last Week
New timelines announced in press releases:
- EPRX, RESOLVE: December 2026. “The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.” SEC filing
- OSTX, OS Therapies MHRA Conditional Marketing Authorization Application (CMAA): early in fourth quarter of 2026. “OS Therapies is pursuing MHRA Conditional Marketing Authorization Application (CMAA) under Project Orbis via its Innovative Licensing and Access Pathway (ILAP), with a submission…” SEC filing
- BNTC, BB-301: mid-2027. “The BB-301 pivotal trial remains on track to begin in mid-2027” SEC filing
Trial status changes on ClinicalTrials.gov:
- VNDA: Phase 3 trial marked completed (2026-10-10). Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) Registry
- ARWR: Phase 3 trial marked completed (2026-10-10). Study of Plozasiran in Adults With Severe Hypertriglyceridemia Registry
- ARWR: Phase 3 trial marked completed (2026-10-09). Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Registry
📄 Key SEC Filings Last Week
Filings that can move a stock, each summarized from the filing itself; financing filings are under Dilution Watch below:
- ARGX, 2026-10-08 (clinical trial): Phase 2 study of FB102 in celiac disease met its primary endpoint, change from baseline in villus height-to-crypt depth ratio at day 78 versus placebo (p=0.0176). The company plans to advance FB102 into Phase 3 development. SEC filing
- ADXN, 2026-10-08 (clinical trial): Spin-out Neurosterix completed Phase 1 studies of NTX-253, an oral M4 PAM for schizophrenia, and plans to advance it into Phase 2 patient studies. Addex holds a 20% equity interest in Neurosterix. SEC filing
- KAPA, 2026-10-06 (clinical trial): Reported interim Phase 2 data for ENV-105 (carotuximab) plus apalutamide in metastatic castration-resistant prostate cancer, with median progression-free survival of 17.7 months versus 2 months for apalutamide alone (P=0.0008). SEC filing
- AVBP, 2026-10-06 (clinical trial): Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed its primary PFS endpoint by BICR: median PFS 11.0 months at 240mg and 8.4 months at 160mg vs 9.5 months control (p=0.0654 for 240mg). Safety was consistent with prior studies. SEC filing
- PCVX, 2026-10-05 (clinical trial): Reported positive topline data from the Phase 3 OPUS-1 adult trial of VAX-31. All 28 serotypes shared with PCV20 and/or PCV21 met noninferiority at the >0.667 threshold, and VAX-31 was well tolerated. OPUS-2 and OPUS-3 results are expected in first half 2027, with BLA submission planned for first half 2028. SEC filing
- VALN, 2026-10-08 (regulatory): Valneva said the UK MHRA revoked the UK marketing authorization for IXCHIQ after a further benefit-risk review by the CHM, with no new safety signal. Valneva disagrees but will not appeal, citing immaterial financial impact. EU, Canada and Brazil licenses are unaffected. SEC filing
- CATX, 2026-10-08 (regulatory): FDA granted Fast Track Designation for PSV359, an FAP-targeted alpha-particle therapy, for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. The drug is in an ongoing Phase 1/2a study for advanced FAP-positive solid tumors. SEC filing
- LPCN, 2026-10-07 (regulatory): Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with male hypogonadism. Licensing partner Verity Pharma plans a Canadian launch by the end of 2026. SEC filing
- BGMS, 2026-10-09 (deal): BGMS seeks stockholder approval for a share exchange with Future NRG Sdn. Bhd. under a June 4, 2026 agreement with a $2,000,000,000 aggregate consideration value, issuing shares to Selling Shareholders who would own over 99.0% of Parent. SEC filing
- CVKD, 2026-10-07 (deal): Cadrenal’s board authorized a formal strategic process to evaluate options to maximize portfolio value, including licensing, asset sales, partnerships or business combinations. The company retained Tungsten Advisors as exclusive advisor and set no deadline; there is no assurance of any transaction. SEC filing
- RGEN, 2026-10-06 (deal): Repligen completed its acquisition of BioLife Solutions. BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock per share, with cash in lieu of fractional shares. SEC filing
- TCRT, 2026-10-09 (listing): Received a Nasdaq delisting notice on Oct 5, 2026 for not meeting the $2,500,000 minimum stockholders’ equity rule, and plans to request a hearing before the Nasdaq Hearings Panel. It is working with a financial advisor on strategic alternatives, with no assurance of compliance. SEC filing
💊 FDA Decisions (PDUFA Dates)
| Date | Ticker | Drug | Indication | Type |
|---|---|---|---|---|
| 2026-10-17 | IRD | Phentolamine Ophthalmic Solution 0.75% | presbyopia | sNDA |
🧪 Phase 2 and 3 Trials Reaching Primary Completion
Estimated primary completion dates from ClinicalTrials.gov: the last patient reaches the main endpoint. Topline results usually follow weeks or months later.
- BMY, 2026-10-15 (Phase 3): A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE Registry
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- ATOS: Phase 2 primary completion in 21 days, score 88/100
- VSTM: Data readout guided for October 2026, window closes in 20 days, score 68/100
- TLSA: Data readout guided for October, window closes in 20 days, score 67/100
💸 Dilution Watch: New Financing Filings
- QUCY: ATM program up to $100M (424B5, 2026-10-09) EDGAR
- MGRX: ATM program (424B5, 2026-10-09) EDGAR
- BIAF: ATM program (424B5, 2026-10-09) EDGAR
- BIAF: registered direct offering (424B5, 2026-10-09) EDGAR
- BIAF: private placement (8-K, 2026-10-09) EDGAR
- FBLG: private placement (8-K, 2026-10-08) EDGAR
- ICU: private placement (8-K, 2026-10-05) EDGAR
- IMNM: private placement (8-K, 2026-10-05) EDGAR
📉 Downside Radar: Trading Far Below a Recent Offering
Of biotech stocks 25% or more below their close on the day of a recent offering, 76% were lower 60 trading days later, median -29% (any biotech on a random day: 53% lower, median -2%). On the radar now:
- DCOY: $1.47, 62% below $3.85, its close on the day of its Sep 23 private placement (new this week)
- GRML: $5.17, 56% below $11.85, its close on the day of its Sep 28 registered direct offering (new this week)
- LEXX: $3.32, 50% below $6.60, its close on the day of its Sep 9 private placement (new this week)
- JUNS: $2.85, 50% below $5.66, its close on the day of its Aug 24 private placement (new this week)
- AMLX: $28.14, 29% below $39.66, its close on the day of its Aug 20 underwritten offering (new this week)
Full Downside Radar and how it was tested →
📈 Last Week’s Biggest Gainers
- APUS +55.34% (volume 13.2x average)
- ZYBT +50.45% (volume 5.0x average)
- PCRX +44.40% (volume 28.0x average)
- PDSB +35.29% (volume 0.7x average)
- CPHI +32.58% (volume 10.9x average)
Earlier weekly catalyst recaps →
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.